Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Executive Summary

Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.

You may also be interested in...



AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact

Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.

AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact

Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.

New AbbVie Guidance Sets High Bar For Post-Humira Pipeline

AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel